Page 19 - B Cell News Today

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.

A new study found increases in resting memory B cell subsets showed strong cross-reactivity against several variants, including Omicron.

Scientists at the La Jolla Institute for Immunology have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.

Infection-fighting B cells retain better memory of the coronavirus spike protein in University Hospital patients who recover from less-severe cases of COVID-19 than in those recovering from severe COVID-19, a new study suggests.

In a new study, published on the bioRxiv* preprint server, scientists showed in a mice model that three doses of the same synthetic peptide vaccine, eliciting an exclusive CD8+ T cell response against one SARS-CoV-2 Spike epitope, protected against lethal SARS-CoV-2 infection, in the absence of neutralizing antibodies. Researchers also showed that the third dose resulted in superior generation of effector-memory T cells in the circulation and tissue-resident memory T (TRM) cells.

Researchers study influenza and SARS-CoV-2 infection models to identify lung memory B cells during viral infection.

A new study demonstrates significantly altered structure and cellularity of Peyer’s patches in deceased COVID-19 patients.

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

Researchers have conducted an investigation to probe the similarity of viral epitopes between bovine coronavirus (BCoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The Lupus Research Alliance proudly announced today 11 research grant recipients in the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas from probing the development and progression of lupus to pointing to potential personalized therapies.